|
Quotes & Info
|
| PLX > SEC Filings for PLX > Form 8-K on 1-Nov-2012 | All Recent SEC Filings |
1-Nov-2012
Other Events
On November 1, 2012, Protalix BioTherapeutics, Inc. and Pfizer Inc. issued a press release announcing that the European Commission (EC) has issued a Commission Decision refusing the Marketing Authorization for taliglucerase alfa, an enzyme replacement therapy (ERT) for the treatment of Gaucher disease. A copy of the press release is filed as Exhibit 99.1.
|
|